All In Biotech

Drug Trial Radar · NCT03936153

Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

An Open-label, Single-arm, Multi-center Phase 2 Study to Evaluate the Efficacy and Safety of Abexinostat as Monotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Last checked: Nov 19, 2026Latest source record: Apr 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

170

Planned (sponsor's estimate)

Start

Jan 20, 2020

Primary completion

Jul 31, 2026

Study completion Aug 31, 2027

Sponsor

Lead sponsor
Xynomic Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
May 3, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

An open-label, single-arm, multi-center phase 2 study to evaluate the efficacy and safety of abexinostat, as monotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

Conditions

  • Diffuse Large B-cell Lymphoma (DLBCL)

Interventions

  • abexinostatDrug

    abexinostat tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical effect by evaluating the objective response rate (ORR)Time frame: up to 56 days

Locations

23 sites in 1 country. Site status is shown where the registry gives one.

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, China · Recruiting

  • China-Japan Friendship Hospital

    Beijing, China · Recruiting

  • Peking University Third Hospital

    Beijing, China · Recruiting

  • West China Hospital, Sichuan University

    Chengdu, China · Recruiting

  • The First Affiliate Hospital of Dalian Medical University

    Dalian, China · Recruiting

  • Fujian Medical University Union Hospital

    Fuzhou, China · Recruiting

  • Fujian Provincial Cancer Hospital

    Fuzhou, China · Recruiting

  • Cancer Center of Guangzhou Medical University

    Guangzhou, China · Recruiting

  • Sun Yai-Sen Memorial Hospital, Sun Yai-Sen University

    Guangzhou, China · Recruiting

  • Zhejiang Cancer Hospital

    Hangzhou, China · Recruiting

  • The Affiliated Tumor Hospital of Harbin Medical University

    Harbin, China · Recruiting

  • The First Hospital of Lanzhou University

    Lanzhou, China · Recruiting

  • Linyi Cancer Hospital

    Linyi, China · Recruiting

  • Nantong Tumor Hospital

    Nantong, China · Recruiting

  • Shanghai Jiao Tong University School Medicine

    Shanghai, China · Recruiting

  • Fudan University Shanghai Cancer Center

    Shanghai, China · Recruiting

  • Second People's Hospital of Shenzhen

    Shenzhen, China · Recruiting

  • The Forth Hospital of Hebei Medical University

    Shijiazhuang, China · Recruiting

  • First Hospital of Shanxi Medical University

    Taiyuan, China · Recruiting

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, China · Recruiting

  • The Affiliated Hospital of Xuzhou Medical University

    Xuzhou, China · Recruiting

  • Henan Cancer Hospital

    Zhengzhou, China · Recruiting

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.